Skip to search formSkip to main contentSkip to account menu

PF-04691502

Known as: PI3K/mTOR Kinase Inhibitor PF-04691502 
An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma.
Myxoid and round cell liposarcoma (MRCL) is a common type of soft tissue sarcoma. The lack of patient-derived tumor xenograft… 
2016
2016
Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells.
2016
2016
Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing
Purpose Gallbladder sarcomatoid carcinoma is a rare cancer with no clinical standard treatment. With the rapid development of… 
2015
2015
mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.
2015
2015
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Identification of genomic alterations defining ovarian carcinoma subtypes may aid the stratification of patients to receive… 
2013
2013
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
2013
2013
PI3K/mTOR dual inhibitor PF-04691502 induces apoptosis of human gastric cancer SGC-7901 cells
AIM: To determine the antitumor effect of PF-04691502,a dual inhibitor of phosphatidylinositol 3-kinase( PI3K) / Akt and… 
2013
2013
Abstract 2100: Preclinical evaluation of PF-04691502 in nasopharyngeal carcinoma.
Nasopharyngeal carcinoma (NPC) is common in Southeast Asia. PF-04691502 (PF) is a novel potent dual inhibitor of PI3K/mTOR… 
2011
2011
Molecular Medicine in Practice PF-04691502 , a Potent and Selective Oral Inhibitor of PI 3 K and mTOR Kinases with Antitumor Activity
Deregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway such as by PTEN loss or PIK3CA mutation occurs frequently… 
2010
2010
Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and negative segments
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC The PI3K pathway plays a role in key cellular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)